Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases

Abstract

BackgroundAsthma is a chronic inflammatory condition well controlled with inhaled therapies. In a small cohort of severe cases there remain a clinical unmet need. Omalizumab is licensed as add-on therapy in severe atopic (IgE-mediated) asthma.AimProspective review of whether treatment with omalizumab over 52 weeks attenuates blood eosinophilia. Secondary endpoints included subjective, objective and healthcare utilisation parameters in the same individuals.MethodsPatients initiated as per NICE guidance on omalizumab therapy were observed and data collected including blood tests (blood eosinophils), subjective (ACT and AQLQ) and health care utilization (critical care and hospital admission days, oral corticosteroid courses and dose alterations) at the 3 timepoints of 52-weeks pre-omalizumab (baseline), 16-week and 52-week post-omalizumab.ResultNine (3M;6F) patients with a mean age of 48 (±12) years were observed. Median baseline eosinophilia was 0.15x10^9/L (IQR 0.02, 0.21), and 0.2 (IQR 0.21, 0.31) and 0.51 (IQR 0.2, 0.71) at 16- and 52-weeks respectively. The table below shows changes in subjective and healthcare utilization parameters.

Parameters	Pre-Omalizumab	16 wks post-Omalizumab	52 wks post-Omalizumab
ACT score	9.6	18.5	19.5
AQLQ score	3.6	5.7	5.4
In-patient Hospital (days)	14.3	0.1	1.3
ITU (days)	0.3	0	0
No. of Steroid Courses	3.1	0.5	0.7
Prednisolone Dose (mg/day)	5.6	1.5	0.2

 

ConclusionOmalizumab treatment over 52 weeks had no impact on blood eosinophil counts but as expected, resulted in improvements on healthcare utilization and subjective parameters. The impact of omalizumab therapy on eosinophilia requires confirmation in larger prospective studies.


Rating:

Share or cite this content

Citations should be made in the following way:
Moshfiq Abeer (Hull, United Kingdom), Moshfiq Abeer, Thompson Joanne, Cummings Helena, Watkins Karen, Jaymin Morjaria. Does omalizumab attenuate blood eosinophilia at 52 weeks; a single centre observation. Eur Respir J 2015; 46: Suppl. 59, 1016

Member's Comments

No comment yet.

Related content which might interest you: Blood eosinophils, exacerbations in the previous year, lung function and ICS dose predict frequent exacerbations in asthma Source: International Congress 2016 – Phenotyping asthma Year: 2016 The role of adherence to inhaled corticosteroids (ICS) in the relationship between blood eosinophilia and asthma control Source: International Congress 2016 – Asthma management in primary care Year: 2016 Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 A treatment algorithm adjusting oral corticosteroid using blood eosinophils reduces exacerbations and improves asthma control, in difficult asthmatics Source: International Congress 2016 – Systemic biomarkers Year: 2016 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 LATE-BREAKING ABSTRACT: Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016 Changes in symptoms, respiratory function, airway inflammation, and airway hyperresponsiveness over 10 year of inhaled corticosteroid therapy in adult asthma patients Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement Source: Annual Congress 2013 –Origins and diagnosis of asthma Year: 2013 Clinical outcomes in non-eosinophilic versus eosinophilic asthma after 12 months specialist management Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Clinical-functional and inflammatory evolution after one year of tracking in patients with asthma according to induced sputum cellularity Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Blood eosinophil dose response to oral corticosteroids in a population of patients with severe asthma Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Effect of 1 year treatment with inhaled corticosteroids with electronically assessed adherence on height growth in children with asthma Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results) Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 Finding asthmatics suitable for omalizumab therapy in a district hospital Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013 Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013